{"filing":{"accession_number":"0001648257-26-000041","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"hcm-20260625x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000041/hcm-20260625x6k.htm"},"events":[{"id":13667,"run_id":12135,"accession_number":"0001648257-26-000041","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces pivotal Phase II clinical trial results for fanregratinib (HMPL-453) in intrahepatic cholangiocarcinoma, demonstrating an objective response rate of 42.5% and median overall survival of 16.6 months. The trial has met its primary endpoint, and the New Drug Application has been accepted for priority review by China's NMPA in December 2025. This is a material clinical and regulatory milestone for a key drug candidate, but it is not a discrete financial event (earnings release), M\u0026A activity, executive change, or other specifically enumerated event type—it is a significant operational/clinical development that would affect investor assessment of the company's pipeline and commercial prospects.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":10875,"accession_number":"0001648257-26-000041","item_number":"EX-99.1","item_title":"hcm-20260625xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces pivotal Phase II clinical trial results for fanregratinib (HMPL-453) in intrahepatic cholangiocarcinoma, demonstrating an objective response rate of 42.5% and median overall survival of 16.6 months. The trial has met its primary endpoint, and the New Drug Application has been accepted for priority review by China's NMPA in December 2025. This is a material clinical and regulatory milestone for a key drug candidate, but it is not a discrete financial event (earnings release), M\u0026A activity, executive change, or other specifically enumerated event type—it is a significant operational/clinical development that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:08:38.242030+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10875,"accession_number":"0001648257-26-000041","item_number":"EX-99.1","item_title":"hcm-20260625xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces pivotal Phase II clinical trial results for fanregratinib (HMPL-453) in intrahepatic cholangiocarcinoma, demonstrating an objective response rate of 42.5% and median overall survival of 16.6 months. The trial has met its primary endpoint, and the New Drug Application has been accepted for priority review by China's NMPA in December 2025. This is a material clinical and regulatory milestone for a key drug candidate, but it is not a discrete financial event (earnings release), M\u0026A activity, executive change, or other specifically enumerated event type—it is a significant operational/clinical development that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:08:38.242030+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-06-25"}]}